Advanced Cell Technology Inc. (OTCBB: ACTC)

Advanced Cell Technology Inc. (ACTC) engages in the research and development of specialized stem-cell technologies for the treatment of various diseases or conditions. The Company’s proprietary methods are intended to bring novel approaches in the area of regenerative medicine. The Company is headquartered in Worcester, Massachusetts.

Source: Reuters.com, SEC Filings.

Financial Summary

Source: Reuters.com, SEC Filings.

Analyst Consensus

No analyst polled by Thomson Reuters rate shares of ACTC.

Investment Highlights

The Company focuses upon three product areas, including Retinal Pigment Epithelium (RPE), Hemangioblast (HG) cells, and Myoblast programs.

The Company believes the RPE program will yield new treatments for the eye disease macular degeneration related to aging, with the first therapy for the treatment of Stargardt’s Disease. The Company’s collaboration with Casey Eye Institute at OHSU has shown positive results supporting efficacy and safety for the treatment of retinal diseases, and intends to file an Investigational New Drug application with the Food and Drug Administration (FDA) by year-end.

The HG and Myoblast programs are intended to offer new therapies for the treatment of cardiac disease, including heart failure, and have recently completed Phase I clinical trials. The FDA has cleared the HG program and Myoblast program (the most advanced of the Company’s portfolio) to enter phase II human trials, which it seeks financing to initiate and eventually complete.

The Company seeks to pursue strategic alliances with other entities primarily interested in furthering stem cell research in the United States. In 2004, the state of California passes Proposition 71, often called the “Stem Cell Initiative,” which provides $3.0 billion in funding over 10 years to further medical therapies from the research of stem cells. The Company will pursue opportunities in collaboration with academia, industry and foundations in the state of California. Other states have passed similar laws or headed for similar legislation including New Jersey, Connecticut, Florida, Illinois, Maryland, New York, Massachusetts and Missouri.

The Company recently announced that it developed novel techniques to generate embryonic stem cells without damaging the embryos, which reopened the debate of the possibility of moral utilization of embryos. Subsequent announcements of successful creations of human embryonic stem-cell lines have bolstered the industry’s image amongst many detractors.

Through the years of research, the Company owns or licenses more than 380 patents and patent applications.

Recent Company News

On October 6, the Company announced that it is up-to-date on its financial statements and filings, and now trades on the OTCBB. The move from the pink sheets increases the Company’s potential investor base and ability to raise additional capital.

Technical Analysis

Source: http://stockcharts.com/h-sc/ui?s=actc

ACTC trades below its 13-day moving average. This bearish sign is significant because the moving average also trends lower.

The MACD for ACTC currently indicates a neutral-to-bearish signal. The MACD is below the signal line, a 9-day moving average of the MACD. The MACD is also below the critical level of 0, which implies the past price action had been negative. Overall, the chart is neutral to bearish in the short term.

Comparative Analysis

Source: Thomson Financial

Insider Trading Activity

Data provided by Thomson Financial

Report Disclaimer

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.